Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PB1046 Injection Clear all
Completed Phase 2 Interventional Results available

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

NCT02808585
View directory record Official record
Conditions
Heart Failure
Interventions
PB1046 Injection, Placebo Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 5, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

NCT01523067
View directory record Official record
Conditions
Essential Hypertension
Interventions
Vasomera (PB1046), 0.9% Sodium Chloride
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 5, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH

NCT03315507
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PB1046 Subcutaneous Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 5, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

NCT03795428
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046) Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 5, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

NCT03556020
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Pemziviptadil (PB1046)
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
26
States / cities
Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 5, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 5, 2026, 6:41 PM EDT